| 3.38 -0.03 (-0.88%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.13  |
1-year : | 4.64 |
| Resists | First : | 3.53 |
Second : | 3.98 |
| Pivot price | 3.17 |
|||
| Supports | First : | 2.81 | Second : | 2.34 |
| MAs | MA(5) : | 3.26 |
MA(20) : | 3.25 |
| MA(100) : | 3.61 |
MA(250) : | 5.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.7 |
D(3) : | 61.1 |
| RSI | RSI(14): 52.8 |
|||
| 52-week | High : | 20.7 | Low : | 2.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CLRB ] has closed below upper band by 16.9%. Bollinger Bands are 57.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.44 - 3.46 | 3.46 - 3.48 |
| Low: | 3.28 - 3.3 | 3.3 - 3.32 |
| Close: | 3.35 - 3.38 | 3.38 - 3.41 |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Tue, 17 Feb 2026
Cellectar Biosciences Expands Global Intellectual Property Estate - Investing News Network
Tue, 17 Feb 2026
New patents back Cellectar bid for EMA OK on Waldenström drug - Stock Titan
Fri, 09 Jan 2026
Cancer-focused biotech maps 2026 push in blood and breast tumors - Stock Titan
Thu, 13 Nov 2025
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 193 (K) |
| Shares Short P.Month | 106 (K) |
| EPS | -8.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -72.4 % |
| Return on Equity (ttm) | -145.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 1.44 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|